Document daXw9D9gGbgYwG1E5Xb7ME5rR

From: Hollenshead, Bernie R SCC Sent: Thursday, September 05,200212:34 PM To: Clegg, Patsy M SCC-CHSE-PC Subject: RE: Benzene Producers in the US There are some 15 or more producers of Bz in the US. However the large ones are Exxon, BP, Dow, Chevron-Phillips, ConocoPhillips, Citgo, and Flinthills(Koch). In oder: Mark Myers,281/870-6790; Hunter Henderlite, 630/961-6982; Robbie Dahlgren,713/978-3349; Mark Graham,832/813-4239; none at Conoco; Phil Reedy,918/495-5232; Greg Richards,316/828-8317. All are commercial types but they shd know the HSE focal point for Bz. Bernie Hollenshead Sales Director - Aromatics Shell Chemical LP One Shell Plaza, P.O. Box 2463, Houston, TX 77252-2463 Tel: +1 713241 3492 Fax: 8540 Email: brhollenshead@shellus.com Internet: http://www.shell.com/chemicals -----Original Message----- From: Clegg, Patsy M SCC-CHSE-PC Sent: Thursday, August 29, 2002 2:40 PM To: Hollenshead, Bernie R SCC Subject: Benzene Producers in the US Bernie, Working on recruiting new sponsors for the benzene study in Shanghai. Would you please provide me with a list of benzene producers in the US. If you have a name and telephone number for a potential contact within the company, that would be great. Also, producers outside the US are being sought. Patsy Clegg Product Steward Shell Chemical LP One Shell Plaza, 910 Louisiana, Houston, TX 77002-4916 Tel: +1 713241 2521 Fax: 3325 Email: pmclegg@shellus.com Internet: http://www.shell.com/chemicals SH ELL-MCCLU RG-065584 A 1 2 Item 3 AHSciences Case-Control Study 4 DP & ME Studies (UCHSC) 5 Irons(T & E) 6 Fudan University 7 Cinpathogen 8 9 Scientific Review Panel 10 Ethics Review Panel 11 External Pathology & Cytogenetics (Cost in UC cost) 12 Exposure Assessment 13 14 API Seed Monies 15 Outside Counsel 16 Communications 17 QAJQC Activities 18 UCHSC Interest 19 Committed funds 20 Contingency 21 22 23 24 GRAND TOTAL 25 Cummulative Interest Earned B Total Research Costs Total Panel Costs Miscellaneous Costs Subtotal API Admin. C Approved 21-Jun-07 $ 3,819,119 $ 20,045,469 $ 1,413,428 $ 444,829 $ 4,847,740 $ 30,570,585 $ 446,950 $ 166,192 $- $ 109,000 $ 722,142 $- $ 245,000 $ 500,000 $ 200,000 $- $ 156,391 $ 1,227,395 $ 2,328,786 $ 33,621,513 $ 1,609,629 $ 35,231,142 $ 343,198 D Approved 7-Aug-08 $ 3,819,119 $ 20,500,602 $ 1,413,428 $ 444,829 $ 4,847,740 31,025,718 $ 446,950 $ 166,192 $- $ 109,000 722,142 $- $ 245,000 $ 500,000 $ 300,000 $- $ 216,391 $ 612,262 1,873,653 33,621,513 $ 1,609,629 $ 35,231,142 $ 505,540 E Approved 23-0ct-08 $ 3,997,919 $ 20,500,602 $ 1,413,428 $ 444,829 $ 4,847,740 31,204,518 $ 487,950 $ 232,858 $- $ 109,000 829,808 $- $ 245,000 $ 500,000 $ 300,000 $- $ 216,391 $ 225,796 1,487,187 33,521,513 $ 1,709,629 $ 35,231,142 $ 538,242 SH ELL-MCCLU RG-065585 A 1 2 3 4 B 5 6 7 Cost Centers Project # 8 9 Income 10 11 Cost Centers 12 UCHSC* 13 Irons-Field Expense* X8105 X8106 14 Applied Health Sciences X8107 15 Fudan University X8108 16 Scientific & Ethics Panels X8109 17 Communications X8103 18 Outside Legal Counsel X8104 19 QA/QC Support X8110 20 API Administrative X8100 21 Exposure Assessment x8111 22 Cinpathogen x8112 23 Committed Contingency 24 Uncommitted Contingency 25 Total Expenses 26 27 Yearly Activity 28 29 Fund Balance Benzene Health Research Consortium Executive Summary Financial Report Thrnllnh e. OR) C D E F G H I J K LM N 0 P Actuals Inception Thru December 2004 Actuals Jan - Dec 2005 Actuals Jan - Dec 2006 Actuals Jan - Dec 2007 ACTUALS ACTUALS Jan - Sept 2008 ACTUALS Program to 9/30/08 tsalance In contract ActualS + balance Thru Sept 08 $ 16,765,693 $ 5,206,657 $ 6,938,163 $ 4,350,896 $ 2,486,785 $ 35,748,194 $ 35,748,194 PROJECTED PROJECTED for 2008 PROJECTED 2009 $ 25,000 $ - 10,137,850 788,486 3,624,030 262,000 4,000,000 262,000 1,570,889 17,526 1,167,733 - 20,500,502 1,330,012 - 20,500,502 - 1,330,012 1,391,014 124,090 548,720 4,007 558,214 76,377 632,124 - 479,142 84,695 3,609,215 289,169 155,014 60,926 3,764,229 350,095 181,713 294,161 76,176 - 95,418 - 43,869 - 81,245 4,309 478,423 298,470 94,600 - 573,023 298,470 64,529 - 856,208 - 104,473 33,706 - 130,475 - 51,918 39,154 1,202 161,327 12,324 - 53,546 64,976 148,213 27,197 3,310,627 2,495 7,642 11,635 142,810 52,394 967,389 1,096 - 198,578 77,814 1,439,034 91,915 4,278,016 159,983 - 28,437 235,720 - 8,178 569,722 - 227,015 313,534 1,439,034 100,093 4,847,738 159,983 - $ 13,942,525 $ 4,731,033 $ 5,206,017 $ 5,871,463 $ 3,000,091 $ 32,751,129 $ 1,152,597 $ 33,903,726 $ 2,823,169 $ 475,624 $ 1,732,146 $ (1,520,567) $ (513,306) $ 2,997,065 0.00 $ 2,823,169 $ 3,298,793 $ 5,030,939 $ 3,510,371 $ 2,997,065 $ 1,844,468 $ 1,844,468 - 48,000 - 60,000 - $ 108,000 10,000 - 10,000 40,000 169,000 50,000 10,000 10,000 100,000 - 470,000 (34,000) - $ 835,000 Page 2 &[PATH]&[FILE] SH ELL-MCCLU RG-065586 Q 1 2 3 4 R S BUDGET 5 PROJECTED 6 End of Program 7 Project Budget 8 Income 9 35,773,194 $ 35,231,142 10 11 Ex[!enses 12 20,510,502 20,500,602 13 1,330,012 1,413,428 14 3,774,229 3,997,919 15 390,095 444,829 16 742,023 720,808 17 348,470 500,000 18 237,015 245,000 19 323,534 300,000 20 1,587,034 1,709,629 21 100,093 109,000 22 5,317,738 4,847,740 23 185,983 $ 216,391 24 - 225,796 25 $ 34,846,726 $ 35,231,142 26 27 28 29 $ 926,468 T Benzene Health Research Consortium Executive Summary Financial Report (Through September 08) Page 3 &[PATH]&[FILE] SH ELL-MCCLU RG-065587 J. Rice 14 August 2006 SHS Cumulative Case Accrual Figures, WHO classification (approximate 6-month increments) Revision 3 - combines data from progress reports and RDI ppt presentations, 2005-2006 3 years of accrual = 6 x 6 mos. AML Lymphoid MDS AA BP Estimated AML accrual & projection July 03 - Dec 04 (3 x 6 months) Cases Cases/ Cum. Cum 6 mos. cases Cases/ 6 mos. 269 90 269 90 261 87 261 87 192 64 192 64 61 20 61 20 25 8 d 25 8d Accrue 500 WHO AML = 6 x 6 mos (3 yr from July 03 = July 06) Jan 05 - July 05 (~1 x 6 months) Cases Cases/ Cum. Cum 6 mos. cases Cases/ 6 mos. 56 56 325 81 55 55 316 79 39 39 231 58 4 4 65 16 2 2 27 7 Accrue 500 WHO AML = 6.5 x 6 mos (3 yr 3 mo from July 03 = Oct 06) Aug 05 - May 06 (~2 x 6 months) Cases Cases/ Cum. cases Cum 6 mos. Cases/ 194a 204a 97 102 519b 520e 6 mos. 87 87 148 74 67 34 379 63 132d 22 53 32 5 Accrue 500 WHO AML = 6 x 6 mos (3 yr from July 03 = July 06; 500 cases actually accrued by May 06) Estimated lympho accrual & projection Accrue 500 WHO lympho = 6 x 6 mos (3 yr from July 03 = July 06) Accrue 500 WHO lympho = 6 x 6 mos (3 yr 3 mo from July 03 = Oct 06) Accrue 500 WHO lympho = 6 x 6 mos (3 yr from July 03 = July 06) a Calculated by subtraction of previously reported cases (Jan 05 - July 05) from cumulative cases reported at Houston meeting or in July 2006 DP_ME_EA Progress Report. b RD Irons' slide #2, Houston, Aug 2006 CFootnote [ C] to Table 1 of DP_ME_EA Progress Report, July 2006 d Aritlunetic errors in first and second versions of this table corrected. SH ELL-MCCLU RG-065588